Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials
Pooled result · Composite gout outcomesResult — go to the resultHazard ratio 0.55 95% CI 0.45–0.67Authors' conclusion
We found that SGLT2 inhibitors significantly reduced the risk of gout in individuals with T2DM/HF. Lack of an association with SUA-lowering effects suggests that metabolic and anti-inflammatory effects of SGLT2 inhibitors may predominantly mediate their anti-gout benefits.
Study context
- Population
- Patients in randomized controlled trials (RCTs) or post hoc analyses (≥1-year duration) of SGLT2 inhibitors, with T2DM and/or heart failure (HF)
- Participants
- 29,776 patients5 RCTs
- Comparison
- SGLT2i vs placebo
- Outcome
- Composite of:
- Gouty arthritis/gout flares
- Commencement of anti-gout drugs (SUA-lowering drugs/colchicine)
Methodological detailsrandom-effects model, meta-regression
- Random-effects model
- Meta-regression
Pooled result
Composite gout outcomes
Hazard ratio
0.55
95% CI 0.45–0.67
P < 0.001
SGLT2ivs Placebo
HR 0.55 (95% CI 0.45–0.67); P < 0.001
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Empagliflozin 10/25 mg trialsSGLT2ivs PlaceboEmpagliflozin 10/25 mg trials; I2 = 0% | 0.68 (0.57–0.81) | |
| Sensitivity analysis excluding empagliflozin trialsSGLT2ivs PlaceboI2 = 0% | 0.46 (0.39–0.55) | |
| 0.20.5125Hazard ratio (log scale) |
Subgroups: baseline HF vs T2DM trials
- Treatment benefits did not differ between HF and T2DM trials
- P for interaction = 0.37
- Benefits greater with dapagliflozin 10 mg and canagliflozin 100/300 mg
- P < 0.01 for subgroup differences
Meta-regression
- No impact of baseline serum uric acid (SUA), SUA lowering on follow-up, diuretic use, or other variables on anti-gout effects
Original publication
Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials. Diabetes Obes Metab. Published 19 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →